Prescription fills for weight loss drugs more than doubled in 2024 despite limited insurance coverage and high costs, according to GoodRx. Zepbound prescriptions surged over 300% in its first year, while Wegovy fills grew by more than 100%. Less than 14% of commercial insurance plans offer unrestricted coverage for these drugs. Patients often face out-of-pocket costs exceeding $2,500 annually, even with insurance. Medicare currently excludes weight loss drugs unless prescribed for other conditions. A Biden-proposed rule could expand access and increase costs, pending Trump's approval.
